Bevastim
Generic Name
bevacizumab-400-mg-injection
Manufacturer
Hypothetical Biopharma Co. (Example)
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| bevastim 400 mg injection | ৳ 52,205.00 | N/A |
Description
Overview of the medicine
Bevastim 400 mg Injection contains Bevacizumab, a recombinant humanized monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF). It is used to treat various types of cancer by inhibiting angiogenesis (the formation of new blood vessels that feed tumors).
Uses & Indications
Dosage
Adults
Dosage varies significantly based on indication and patient body weight or body surface area (BSA). Typically 5 mg/kg, 7.5 mg/kg, 10 mg/kg, or 15 mg/kg intravenously every 2 or 3 weeks.
Elderly
No specific dose adjustments required for elderly patients based on age, but close monitoring is recommended due to potential age-related comorbidities.
Renal_impairment
No specific dose adjustments are typically required for renal impairment, but caution is advised and patients should be monitored for adverse effects.
How to Take
For intravenous infusion only. Must be diluted in 0.9% Sodium Chloride injection prior to administration. Infusion should be administered over 30 to 90 minutes, depending on the dose and patient tolerance. Do not administer as an intravenous push or bolus.
Mechanism of Action
Bevacizumab binds to and inhibits Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis. By blocking VEGF, Bevacizumab prevents the formation of new blood vessels and starves existing tumors, thereby slowing tumor growth and metastasis.
Pharmacokinetics
Onset
Clinical effects are observed over several treatment cycles; initial anti-angiogenic effects may be rapid.
Excretion
Eliminated primarily through catabolism; no specific excretory organs identified.
Half life
Approximately 18-20 days (range 11-50 days).
Absorption
Administered intravenously, resulting in 100% bioavailability.
Metabolism
Catabolized via proteolytic degradation, similar to endogenous IgGs.
Side Effects
Contraindications
- •Hypersensitivity to Bevacizumab or any component of the formulation.
- •Severe or recurrent hemorrhage (e.g., hemoptysis, gastrointestinal bleeding).
- •Untreated CNS metastases (in some indications).
Drug Interactions
Sunitinib
Increased risk of microangiopathic hemolytic anemia with Bevacizumab and Sunitinib combination.
Other anti-cancer agents
Generally used in combination; monitor for additive toxicities.
Platinum-based chemotherapy
Potential increased risk of hemorrhage; monitor closely.
Storage
Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light. Do not shake. Diluted solution should be used immediately or stored at 2°C to 8°C for up to 24 hours.
Overdose
No specific antidote for Bevacizumab overdose. Management should be symptomatic and supportive. Close monitoring for adverse effects is essential.
Pregnancy & Lactation
Contraindicated during pregnancy due to potential for fetal harm; use effective contraception during treatment and for 6 months after the last dose. Avoid breastfeeding during treatment and for 6 months after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years when stored as recommended.
Availability
Available in hospitals and specialized oncology pharmacies
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA for biosimilar)
Patent Status
Patent expired for original molecule; biosimilars available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
